Reading SGHT? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track SGHT free→Reading SGHT? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track SGHT free→QuarterlyIQ Insights · SGHT
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Results of Operations and Financial Condition On May 6, 2026, Sight Sciences, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this “Current Report").*
Regulation FD Disclosure. On April 22, 2026, Sight Sciences, Inc. (the “Company”) received notification that the U.S. District Court for the District of Delaware (the “Court”) entered its final judgment (the “Final Judgment”) regarding the patent infringement case (the “Litigation”) filed by the Company in September 2021 against Alcon Inc., Alcon Vision, LLC, Alcon Research, LLC, and Ivantis, Inc. (collectively, “Alcon”). The Company had asserted that Alcon’s sale of the Hydrus® Microstent (“…
Regulation FD Disclosure. On March 30, 2026, Sight Sciences, Inc. (the “Company”) issued a press release announcing that the U.S. District Court for the District of Delaware (the “Court”) issued an order preserving the jury’s verdict of willful infringement in the patent infringement case (the “Litigation”) filed by the Company in September 2021 against Alcon Inc., Alcon Vision, LLC, Alcon Research, LLC, and Ivantis, Inc. (collectively, “Alcon”). The Company had asserted that Alcon’s sale of…
Results of Operations and Financial Condition On March 4, 2026, Sight Sciences, Inc. (the “Company”) issued a press release announcing its financial results for the year and quarter ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this “Current Report").*
Entry into a Material Definitive Agreement On January 29, 2026, Sight Sciences, Inc. (the “Company”) entered into that certain Second Amendment to Multi-Tenant Space Lease (the “Second Amendment”) with Deerfield Campbell, LLC (the “Lessor”), for the Company’s headquarters located at 4040 Campbell Avenue (Suites 100 and 120), Menlo Park, California 94025. The Second Amendment amends that certain Multi-Tenant Space Lease, dated February 5, 2021, and that certain Commencement Date/Acceptance Agr…
by reference. The information provided in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such f…
Results of Operations and Financial Condition On November 6, 2025, Sight Sciences, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this “Current Report).*
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Promotion of Alison Bauerlein to Chief Operating Officer Effective as of November 5, 2025, the board of directors of the Company (the “Board”) promoted Alison Bauerlein to the position of Chief Operating Officer of the Company. Ms. Bauerlein will also serve as the Company’s Principal Operating Officer. In connection with her appointment as Chief Ope…
Other Events. Two Medicare Administrative Contractors (“MACs”), Novitas and FCSO, each established jurisdiction-wide pricing for CPT code 0563T (evacuation of meibomian glands, using heat delivered through wearable, open-eye eyelid treatment devices and manual expression, bilateral), which describes the procedure performed with the Company’s TearCare® System and related accessories (TearCare). The Medicare fee schedule amount of $1,141.59 is effective for dates of service on and after January…
Entry into a Material Definitive Agreement. Third Amendment to Loan and Security Agreement On September 30, 2025 (the “Amendment Date”), Sight Sciences, Inc. (the “Company”) entered into a third amendment (the “Amendment”) to its Loan and Security Agreement (as amended, the “Hercules Loan Agreement”) with Hercules Capital, Inc. (“Hercules”) and certain of its affiliates (collectively with Hercules, the “Lenders”) entered into in January 2024. The Hercules Loan Agreement provides for a senior…
Regulation FD Disclosure The Company reaffirms its prior revenue guidance for the year ending December 31, 2025 of $72.0 million to $76.0 million and reaffirms its expectation for third quarter 2025 surgical glaucoma revenue to be down by mid-single digits compared to the same period in the prior year. In addition, the Company estimates the workforce reductions associated with the Plan alone will yield savings of approximately $11.9 million on an annualized basis. The Company is updating its…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Effective August 31, 2025 (the “Separation Date”), Matthew Link will step down as the Company’s Chief Commercial Officer to pursue other opportunities. The Company appreciates Mr. Link’s many contributions over the past years and his agreement to provide transition services on a consulting basis through September 30, 2025, or such later date as the…
Costs Associated with Exit or Disposal Activities On August 27, 2025, Sight Sciences, Inc. (the “Company”) informed its employees that it is implementing a targeted plan, commencing immediately, intended to reduce operating expenses, improve cost efficiencies, and better align its operating structure for long-term, profitable growth (the “Plan”). The Plan is designed to optimize the Company’s operating structure, help support the Company’s cash position, drive enhanced focus on the Company’s…
Results of Operations and Financial Condition On August 7, 2025, Sight Sciences, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.*
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As previously disclosed, on April 21, 2025, the Board of Directors (the “Board”) of Sight Sciences, Inc. (the “Company”), upon the recommendation of its Nominating and Corporate Governance Committee, appointed Gerhard F. Burbach to the Board. Mr. Burbach has been appointed to serve on the Audit Committee.
Results of Operations and Financial Condition On May 8, 2025, Sight Sciences, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended March 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.*
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On April 21, 2025, the Board of Directors (the “Board”) of Sight Sciences, Inc. (the “Company”), upon the recommendation of its Nominating and Corporate Governance Committee, appointed Gerhard F. Burbach to the Board. Mr. Burbach will serve as a Class II director for a term expiring at the Company’s annual meeting of stockholders to be held in 2026…
Results of Operations and Financial Condition On March 5, 2025, Sight Sciences, Inc. (the "Company") issued a press release announcing its financial results for the year and quarter ended December 31, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.*
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Compensatory Arrangements of Certain Executive Officers On January 24, 2025, the Compensation Committee (the “Compensation Committee”) of the Board of Directors of Sight Sciences, Inc. (the “Company”) approved annual base salaries and target cash incentive bonus opportunities for the fiscal year ending December 31, 2025 (“Fiscal 2025”) for certain…
of this Current Report, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. SIGNATURES Pursuant to the…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.